Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Sacubitril or its saltsPDL I JAN / 16
Salbutamol and its saltsF1 I SEP / 98
Salicylic acidPDL

when sold in topical formulations containing salicylic acid at concentrations greater than 20% and/or with a pH less than 3.0, except when sold to be applied to warts, corns or calluses

I DEC / 14
Salicylic acid and its salts when sold to be applied to warts, corns or calluses in topical preparations in concentrations greater than 40% II DEC / 14
Salicylic acid and its salts.

in topical preparations in concentrations up to and including 40% (except when sold in topical formulations containing salicylic acid at concentrations greater than 20% and/or with a pH less than 3.0 for a use other than to be applied to warts, corns and calluses)

U DEC / 14
Salmeterol and its saltsF1 I SEP / 98
Salsalate and its salts and derivativesF1 I SEP / 98
Sapropterin or its saltsPDL I DEC / 13
Saquinavir and its salts and derivativesF1 I SEP / 98
Saralasin and its saltsF1 I SEP / 98
SargramostinF1 I SEP / 98
SarilumabPDL I APR / 17
SarolanerPDL

for veterinary use

I AUG / 16
Saxagliptin or its saltsPDL I DEC / 13
Scopolamine and its salts hyoscine, except Hyoscine butylbromide, when recommended for parenteral use II AUG / 16
SecobarbitalC1 I JUN / 02
SecukinumabPDL I MAY / 15
Selegiline and its saltsF1 I SEP / 98
Selenium in injectable form for parenteral nutrition I JAN / 03
Senna and its extracts and derivatives U
Sermorelin and its saltsF1 I SEP / 98
Sertraline and its saltsF1 I SEP / 98
Sevelamer and its saltsF1 I DEC / 01
SevofluranePDL I DEC / 13
Sex hormones (natural or synthetic)PDL

for human use, including but not limited to conjugated estrogens, desogestre, dienogest, estradiol benzoate, estradiol(hemihydrate), estrone, ethinyl estradiol, ethynodiol diacetate, etonogestrel, levonogestrel, medroxyprogesterone acetate, norelgestromin, norethindrone acetate, norgestimate, progesterone except as listed in the PDL

I AUG / 15
Sibutramine and its saltsF1 I SEP / 06
SigmodalC2 I JUN / 02
Sildenafil and its saltsF1 I MAY / 00
Silodosin or its salts or derivativesPDL I DEC / 13
SiltuximabPDL I DEC / 14
Silver nitrate II SEP / 98
SimvastatinF1 I SEP / 98
Sincalide II SEP / 98
Sirolimus and its derivativesF1 I JUL / 03
Sitagliptin and its saltsF1 I OCT / 09
Sitaxentan and its saltsF1 I JUN / 08
Sodium acetate for parenteral use II SEP / 98
Sodium acetate in injectable form for parenteral nutrition I JAN / 03
Sodium biphosphate

for parenteral use

II SEP / 98
Sodium biphosphate.

cathartics

III SEP / 98
Sodium bromideF1 I SEP / 98
Sodium chloride single ingredient solutions for parenteral or ophthalmic use in concentrations of more than 0.9% [NOTE: Does not apply to contact lens solutions intended to be rinsed off prior to insertion into eye] II OCT / 98
Sodium chloride in injectable form for parenteral nutrition I JAN / 03
Sodium citrate for parenteral use II SEP / 98
Sodium cromoglicate (cromoglycate) in solutions in concentrations of 2% or less for ophthalmic or nasal use III SEP / 98
Sodium fluoride (see Fluoride)F2 in solid oral dosage forms containing more than 1 mg of fluoride ion I SEP / 98
Sodium iodide for sclerosing II SEP / 98
Sodium iodine in injectable form for parenteral nutrition I JAN / 03
Sodium nitritePDL

when indicated for administration by injection and sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning

I JUN / 15
Sodium nitroprusside and its saltsF1 I SEP / 98
Sodium phosphate for parenteral use II SEP / 98
Sodium phosphate in injectable form for parenteral nutrition I JAN / 03
Sodium phosphate. cathartics III SEP / 98
Sodium picosulphate

for oral purgatives, 10 mg per pack (when found in preparations with magnesium oxide 3.5 g and citric acid 12 g)

II JAN / 10
Sodium polystyrene sulfonateF1 I SEP / 98
Sodium tartrate U
Sodium tetradecylsulfate II SEP / 98
Sofosbuvir or its saltsPDL I FEB / 14
Solifenacin and its saltsF1 I OCT / 07
SomatostatinF1 I SEP / 98
SomatremF1 I SEP / 98
SomatropinF1 I SEP / 98
Sorafenib and its saltsF1 I APR / 08
Sotalol and its saltsF1 I SEP / 98
Spectinomycin and its salts and derivativesF2 I SEP / 98
Spiramycin and its salts and derivativesF2 I SEP / 98
SpironolactoneF1 I SEP / 98
StanozololC3 I JUN / 02
StavudineF1 I SEP / 98
StenboloneC3 I JUN / 02
Stramonium, its preparations, extracts and compounds II SEP / 98
Streptokinase as a debriding agent II SEP / 98
Streptokinase/streptodornaseD I SEP / 98
Streptomycin and its salts and derivativesF2 I SEP / 98
StreptozocinF1 I SEP / 98
Strontium and its salts for parenteral use II SEP / 98
Strontium bromideF1 I SEP / 98
Succinimide and its salts and derivativesF1 except those compounds used for decontaminating water I SEP / 98
Succinylcholine and its saltsF1 I SEP / 98
SucralfateF1 I SEP / 98
SufentanilN I JUN / 02
Sulconazole and its saltsF1 I SEP / 98
Sulfinpyrazone and its saltsF1 I SEP / 98
Sulindac and its saltsF1 I SEP / 98
Sulphonamides and their salts and derivativesF2 I SEP / 98
Sulphones and their derivativesF1 I SEP / 98
Sumatriptan and its saltsF1 I SEP / 98
Sunitinib and its saltsF1 I OCT / 07
Suprofen and its saltsF1 I SEP / 98
Sutilains II SEP / 98
Suxamethonium chlorideF1 I SEP / 98
Synthetic cannabinoid receptor type-1 agonists, their salts, derivatives, isomers, and salts of derivatives and isomersN

with the exception of ((3S)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)-1-naphthalenyl-methanone (WIN 55,212-3) and its salts - as listed in the schedules to the Controlled Drugs and Substances Act and the Narcotic Control Regulations

I JUL / 15

92 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled